Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    European urology focus. 2015 May 28. pii: S2405-4569(15)00004-8. doi: 10.1016/j.euf.2014.10.003
    Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy.
    Kluth LA1,  Xylinas E2,  Rieken M3,  Kent M4,  Ikeda M5,  Matsumoto K6,  Hagiwara M7,  Kikuchi E8,  Bing MT9,  Gupta A10,  Sewell JM11,  Konety BR12,  Todenhöfer T13,  Schwentner C14,  Masson-Lecomte A15,  Vordos D16,  Roghmann F17,  Noldus J18,  Razmaria AA19,  Smith ND20,  Comploj E21,  Pycha A22,  Rink M23,  Baniel J24,  Mano R25,  Novara G26,  Aziz A27,  Fritsche HM28,  Brisuda A29,  Bivalacqua T30,  Gontero P31,  Boorjian SA32,  Vickers AJ33,  Shariat SF34
    Author information
    1Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
    2Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.
    3Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, University Hospital Basel, Basel, Switzerland.
    4Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    5Department of Urology, Kitasato University School of Medicine, Minami-ku, Sagamihara, Kanagawa, Japan.
    6Department of Urology, Kitasato University School of Medicine, Minami-ku, Sagamihara, Kanagawa, Japan.
    7Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
    8Department of Urology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
    9Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
    10Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
    11Department of Urology, University of Minnesota School of Medicine, Minneapolis, MN, USA.
    12Department of Urology, University of Minnesota School of Medicine, Minneapolis, MN, USA.
    13Department of Urology, University Medical Hospital of Tuebingen, Tuebingen, Germany.
    14Department of Urology, University Medical Hospital of Tuebingen, Tuebingen, Germany.
    15Department of Urology, Hôpital Henri Mondor Créteil, Créteil, France.
    16Department of Urology, Hôpital Henri Mondor Créteil, Créteil, France.
    17Department of Urology, Ruhr University Bochum, Marienhospital, Herne, Germany.
    18Department of Urology, Ruhr University Bochum, Marienhospital, Herne, Germany.
    19Department of Surgery, Section of Urology, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA.
    20Department of Surgery, Section of Urology, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA.
    21Department of Urology, General Hospital of Bolzano, Bolzano, Italy.
    22Department of Urology, General Hospital of Bolzano, Bolzano, Italy.
    23Department of Urology, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
    24Department of Urology, Rabin Medical Center, Petah-Tikva, Israel.
    25Department of Urology, Rabin Medical Center, Petah-Tikva, Israel.
    26Department of Surgical, Oncological and Gastroenterologic Sciences, Urology Clinic, University of Padua, Padua, Italy.
    27Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    28Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    29Department of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University of Praha, Praha, Czech Republic.
    30Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
    31Department of Urology, Molinette University Hospital, Torino, Italy.
    32Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA.
    33Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    34Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Division of Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: sfshariat@gmail.com.
    Abstract

    BACKGROUND: Although the natural history of urothelial carcinoma of the bladder (UCB) from radical cystectomy (RC) to disease recurrence (DR) has been investigated intensively, the course of patients who have experienced DR after RC for UCB remains poorly understood.

    OBJECTIVE: To evaluate the prognostic value of the Bajorin criteria that consists of two risk factors: Karnofsky performance status (KPS) and the presence of visceral metastases (VMs) in patients with DR after RC for UCB. Furthermore, to identify additional factors associated with cancer-specific mortality (CSM) and thus build a multivariable model to predict survival after DR.

    DESIGN, SETTING, AND PARTICIPANTS: We identified 967 patients with UCB who underwent RC at 17 centers between 1979 and 2012 and experienced DR. Of these, 372 patients had complete data we used for analysis.

    OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable Cox regressions analysis was performed. We used a forward stepwise selection process for our final multivariable model.

    RESULTS AND LIMITATIONS: Within a median follow-up of 18 mo, 266 patients died of disease. Cancer-specific survival at 1 yr was 79%, 76%, and 47% for patients with no (n=105), one (n=180), and two (n=87) risk factors (p<0.001; c-index: 0.604). On multivariable analyses, we found that KPS <80%, higher American Society of Anesthesiologists score, anemia, leukocytosis, and shorter time to DR (all p values <0.034) were independently associated with increased CSM. The combination of time to DR and KPS resulted in improved discrimination (c-index: 0.694).

    CONCLUSIONS: We confirmed the prognostic value of KPS and VMs in patients with DR following RC for UCB. We also found several other clinical variables to be associated with worse CSM. We developed a model for predicting survival after DR inclusive of time to DR and KPS assessed at DR. If validated, this model could help clinical trial design.

    PATIENT SUMMARY: We developed a model to predict survival following disease recurrence after radical cystectomy for urothelial carcinoma of the bladder, based on time to disease recurrence and Karnofsky performance status.


    Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

    KEYWORDS: Bladder cancer, Disease recurrence, Metastasis, Model, Prognosis, Survival, Transitional cell carcinoma, Urothelial carcinoma of the bladder

    Publikations ID: 28723361
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt